Drew Weissman

38.9k total citations · 45 hit papers
230 papers, 23.4k citations indexed

About

Drew Weissman is a scholar working on Molecular Biology, Immunology and Infectious Diseases. According to data from OpenAlex, Drew Weissman has authored 230 papers receiving a total of 23.4k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Molecular Biology, 84 papers in Immunology and 61 papers in Infectious Diseases. Recurrent topics in Drew Weissman's work include RNA Interference and Gene Delivery (85 papers), HIV Research and Treatment (49 papers) and Immunotherapy and Immune Responses (36 papers). Drew Weissman is often cited by papers focused on RNA Interference and Gene Delivery (85 papers), HIV Research and Treatment (49 papers) and Immunotherapy and Immune Responses (36 papers). Drew Weissman collaborates with scholars based in United States, China and Botswana. Drew Weissman's co-authors include Katalin Karikó, Norbert Pardi, Michael J. Hogan, Houping Ni, Frederick Porter, Hiromi Muramatsu, Michael Buckstein, Mohamad‐Gabriel Alameh, John Capodici and János Ludwig and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Drew Weissman

224 papers receiving 22.8k citations

Hit Papers

mRNA vaccines — a new... 1996 2026 2006 2016 2018 2005 2008 2021 2004 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. mRNA vaccines — a new era in vaccinology
    2018 3.1k citations Norbert Pardi, Drew Weissman et al. Nature Reviews Drug Discovery profile →
  2. Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
    2005 1.8k citations Houping Ni, Drew Weissman et al. profile →
  3. Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
    2008 1.3k citations Hiromi Muramatsu, Drew Weissman et al. Molecular Therapy profile →
  4. mRNA vaccines for infectious diseases: principles, delivery and clinical translation
    2021 934 citations Drew Weissman et al. Nature Reviews Drug Discovery profile →
  5. mRNA Is an Endogenous Ligand for Toll-like Receptor 3
    2004 854 citations Houping Ni, Drew Weissman et al. profile →
  6. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
    2015 688 citations Norbert Pardi, Steven Tuyishime et al. Journal of Controlled Release profile →
  7. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
    2011 655 citations Hiromi Muramatsu, Drew Weissman et al. profile →
  8. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages
    1999 488 citations Drew Weissman et al. Proceedings of the National Academy of Sciences profile →
  9. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
    2010 478 citations Hiromi Muramatsu, Drew Weissman et al. profile →
  10. An ionizable lipid toolbox for RNA delivery
    2021 415 citations Xuexiang Han, Mohamad‐Gabriel Alameh et al. Nature Communications profile →
  11. Nanomaterial Delivery Systems for mRNA Vaccines
    2021 408 citations Mohamad‐Gabriel Alameh, Drew Weissman et al. Vaccines profile →
  12. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation
    1996 392 citations Drew Weissman et al. profile →
  13. Recent advances in mRNA vaccine technology
    2020 346 citations Norbert Pardi, Drew Weissman et al. profile →
  14. Tuberculosis and lung damage: from epidemiology to pathophysiology
    2018 322 citations Drew Weissman et al. profile →
  15. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration
    2021 291 citations Mohamad‐Gabriel Alameh, Drew Weissman et al. profile →
  16. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
    2017 267 citations Norbert Pardi, Hiromi Muramatsu et al. Nature Communications profile →
  17. Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding Erythropoietin
    2012 223 citations Hiromi Muramatsu, Drew Weissman et al. Molecular Therapy profile →
  18. Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device
    2021 222 citations Sarah J. Shepherd, Claude C. Warzecha et al. profile →
  19. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
    2022 218 citations Colleen Furey, Hiromi Muramatsu et al. Science profile →
  20. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice
    2020 207 citations Barbara L. Mui, Ying K. Tam et al. Molecular Therapy profile →
  21. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies
    2018 201 citations Norbert Pardi, Barbara L. Mui et al. Nature Communications profile →
  22. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
    2021 183 citations István Tombácz, Hamna Shahnawaz et al. Molecular Therapy profile →
  23. In vivo hematopoietic stem cell modification by mRNA delivery
    2023 176 citations Houping Ni, Barbara L. Mui et al. Science profile →
  24. Ionizable lipid nanoparticles for in utero mRNA delivery
    2021 160 citations Rachel Riley, Mohamad‐Gabriel Alameh et al. profile →
  25. PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake
    2018 154 citations Hamideh Parhiz, Vladimir V. Shuvaev et al. Journal of Controlled Release profile →
  26. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
    2023 147 citations Xuexiang Han, Mohamad‐Gabriel Alameh et al. profile →
  27. Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer
    2023 132 citations Hiromi Muramatsu, Mohamad‐Gabriel Alameh et al. profile →
  28. Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
    2022 124 citations Lulu Xue, Ningqiang Gong et al. profile →
  29. One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
    2021 123 citations Elena N. Atochina‐Vasserman, Nathan Ona et al. profile →
  30. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
    2023 123 citations Xuexiang Han, Ningqiang Gong et al. Nature Communications profile →
  31. mRNA-based therapeutics: looking beyond COVID-19 vaccines
    2024 112 citations Hamideh Parhiz, Elena N. Atochina‐Vasserman et al. profile →
  32. In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
    2023 108 citations Ningqiang Gong, Alvin J. Mukalel et al. profile →
  33. Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA
    2021 103 citations Ying K. Tam, Norbert Pardi et al. Nature Communications profile →
  34. mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent
    2021 102 citations Gunjan Arora, Norbert Pardi et al. profile →
  35. Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy
    2023 101 citations Alex G. Hamilton, Ajay S. Thatte et al. profile →
  36. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
    2021 93 citations David R. Martinez, Alexandra Schäfer et al. Science profile →
  37. Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells
    2022 90 citations Xuexiang Han, Mohamad‐Gabriel Alameh et al. Journal of Controlled Release profile →
  38. The Unexpected Importance of the Primary Structure of the Hydrophobic Part of One-Component Ionizable Amphiphilic Janus Dendrimers in Targeted mRNA Delivery Activity
    2022 87 citations Elena N. Atochina‐Vasserman, Nathan Ona et al. profile →
  39. High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models
    2024 83 citations Lulu Xue, Alex G. Hamilton et al. Nature Communications profile →
  40. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
    2023 68 citations Sarah J. Shepherd, Xuexiang Han et al. Proceedings of the National Academy of Sciences profile →
  41. Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
    2023 66 citations Alex G. Hamilton, Ningqiang Gong et al. profile →
  42. Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals
    2023 65 citations Paulo J.C. Lin, Ying K. Tam et al. profile →
  43. Enhancing in situ cancer vaccines using delivery technologies
    2024 64 citations Ningqiang Gong, Mohamad‐Gabriel Alameh et al. Nature Reviews Drug Discovery profile →
  44. Physicochemical Targeting of Lipid Nanoparticles to the Lungs Induces Clotting: Mechanisms and Solutions
    2024 52 citations Drew Weissman, Vladimir R. Muzykantov et al. profile →
  45. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease
    2023 46 citations Gunjan Arora, Thomas Hart et al. Molecular Therapy profile →

Peers

Drew Weissman
Comparison fields: 5 of 177
  • Molecular Biology 13.8k
  • Immunology 7.6k
  • Infectious Diseases 6.1k
  • Genetics 2.9k
  • Epidemiology 2.7k
Replace Yoshiharu Matsuura with:
Yoshiharu Matsuura Japan
David B. Weiner United States
Martin F. Bachmann Switzerland
Bali Pulendran United States
Philip L. Felgner United States
David A. Jans Australia
Dennis M. Klinman United States
James C. Paulson United States
Dimiter S. Dimitrov United States
Shane Crotty United States
Yoshiharu Matsuura Japan View profile →
Citations per field, relative to Drew Weissman
Drew Weissman · 1×
Citations per year, relative to Drew Weissman
Drew Weissman · 1×

Countries citing papers authored by Drew Weissman

Since Specialization
Citations

This map shows the geographic impact of Drew Weissman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drew Weissman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drew Weissman more than expected).

Fields of papers citing papers by Drew Weissman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Drew Weissman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Drew Weissman. The network helps show where Drew Weissman may publish in the future.

Co-authorship network of co-authors of Drew Weissman

This figure shows the co-authorship network connecting the top 25 collaborators of Drew Weissman. A scholar is included among the top collaborators of Drew Weissman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Drew Weissman. Drew Weissman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA
2025 ·npj Vaccines ·(unknown), (unknown), James T. Gordy, Mohamad‐Gabriel Alameh, (unknown), (unknown), Elizabeth Glass, Yevel Flores-García, Ying K. Tam, (unknown), (unknown), Drew Weissman, (unknown), (unknown)
1
2
Cytokine mRNA Delivery and Local Immunomodulation in the Placenta Using Lipid Nanoparticles
2025 ·Advanced Therapeutics ·(unknown), J. Lynn Fink, (unknown), (unknown), Katherine M. Nelson, (unknown), Mohamad‐Gabriel Alameh, Drew Weissman, Jason P. Gleghorn, Rachel Riley
1
3
In vivo chimeric antigen receptor (CAR)-T cell therapy
2025 ·Nature Reviews Drug Discovery ·(unknown), Andrew M. Scharenberg, Kevin M. Friedman, Lin T. Guey, Robert Hofmeister, James I. Andorko, Michael Klichinsky, Frank Neumann, Jagesh V. Shah, (unknown), Kyle Trudeau, Drew Weissman, Matthias T. Stephan, Christian J. Buchholz, Carl H. June
4
4
An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses
2025 ·Science Immunology ·(unknown), Anthony T. Phan, Mohamad‐Gabriel Alameh, Garima Dwivedi, (unknown), David A. Christian, Ying K. Tam, (unknown), (unknown), (unknown), (unknown), Colleen Furey, Phillip Scott, Robert H. Vonderheide, Scott E. Hensley, Ross M. Kedl, Drew Weissman, Christopher A. Hunter
11
5
Innate and Adaptive Immune Parameters following mRNA Vaccination in Mice
2024 ·Vaccines ·Srinivasa Reddy Bonam, (unknown), (unknown), Yuejin Liang, Xuxiang Zhang, Zhi Wei, Mohamad‐Gabriel Alameh, Drew Weissman, Haitao Hu
7
6
Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection
2024 ·npj Vaccines ·Elena N. Atochina‐Vasserman, Lisa C. Lindesmith, Carmen Mirabelli, Nathan Ona, Erin K. Reagan, Paul D. Brewer-Jensen, (unknown), Hamna Shahnawaz, (unknown), (unknown), Michael L. Mallory, Mark R. Zweigart, (unknown), Barbara L. Mui, Ying K. Tam, Christiane E. Wobus, Ralph S. Baric, Drew Weissman
4
7
CD8+ T cells exacerbate AD-like symptoms in mouse model of amyloidosis
2024 ·Brain Behavior and Immunity ·Xin Wang, (unknown), Monica Bodogai, Ross A. McDevitt, (unknown), Fedor Gusev, Emeline Ragonnaud, (unknown), (unknown), (unknown), (unknown), Drew Weissman, Hellen Ishikawa‐Ankerhold, Eitan Okun, Е. И. Рогаев, Arya Biragyn
9
8
In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors
2024 ·Nature Communications ·Xuexiang Han, Junchao Xu, Ying Xu, Mohamad‐Gabriel Alameh, Lulu Xue, Ningqiang Gong, Rakan El‐Mayta, Rohan Palanki, Claude C. Warzecha, Gan Zhao, Andrew E. Vaughan, James M. Wilson, Drew Weissman, Michael J. Mitchell
41
9
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
2024 ·Nature Materials ·Ningqiang Gong, Wenqun Zhong, Mohamad‐Gabriel Alameh, Xuexiang Han, Lulu Xue, Rakan El‐Mayta, Gan Zhao, Andrew E. Vaughan, (unknown), Fengyuan Xu, Alex G. Hamilton, Dongyoon Kim, Junchao Xu, Junhyong Kim, Xucong Teng, Jinghong Li, Xing‐Jie Liang, Drew Weissman, Wei Guo, Michael J. Mitchell
31
10
High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models breakdown →
2024 ·Nature Communications ·Lulu Xue, Alex G. Hamilton, Gan Zhao, Zebin Xiao, Rakan El‐Mayta, Xuexiang Han, Ningqiang Gong, Xinhong Xiong, Junchao Xu, (unknown), Sarah J. Shepherd, Alvin J. Mukalel, Mohamad‐Gabriel Alameh, Jiaxi Cui, Karin Wang, Andrew E. Vaughan, Drew Weissman, Michael J. Mitchell
83
11
Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity
2023 ·npj Vaccines ·Tapas Patra, Keith Meyer, Yuki Haga, Erin K. Reagan, Drew Weissman, Ranjit Ray
23
12
Development of an mRNA-lipid nanoparticle vaccine against Lyme disease breakdown →
2023 ·Molecular Therapy ·(unknown), Gunjan Arora, Thomas Hart, Emily Bettini, Brian T. Gaudette, Hiromi Muramatsu, István Tombácz, Taku Kambayashi, Ying K. Tam, Dustin Brisson, David Allman, Michela Locci, Drew Weissman, Erol Fikrig, Norbert Pardi
46
13
DELAYED INTRASPINAL DELIVERY OF MRNAS ENCODING A COMBINATION OF CYTOKINES AND GDNF PROMOTES MORPHOLOGICAL AND FUNCTIONAL RECOVERY FOLLOWING SPINAL CORD INJURY
2023 ·IBRO Neuroscience Reports ·(unknown), Krisztián Pajer, (unknown), Annamária Marton, (unknown), (unknown), Drew Weissman, (unknown), Csaba Vízler, Paulo J.C. Lin, Ying K. Tam, Norbert Pardi, Antal Nógrádi
1
14
Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach
2023 ·Bioactive Materials ·(unknown), Katherine M. Nelson, (unknown), (unknown), Mohamad‐Gabriel Alameh, Drew Weissman, (unknown), Jason P. Gleghorn, Rachel Riley
33
15
Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines breakdown →
2023 ·Proceedings of the National Academy of Sciences ·Sarah J. Shepherd, Xuexiang Han, Alvin J. Mukalel, Rakan El‐Mayta, Ajay S. Thatte, Jingyu Wu, Marshall S. Padilla, Mohamad‐Gabriel Alameh, (unknown), Daeyeon Lee, Drew Weissman, David Issadore, Michael J. Mitchell
68
16
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice breakdown →
2021 ·Science ·David R. Martinez, Alexandra Schäfer, Sarah R. Leist, Gabriela De la Cruz, Ande West, Elena N. Atochina‐Vasserman, Lisa C. Lindesmith, Norbert Pardi, Robert Parks, Maggie Barr, Dapeng Li, Boyd L. Yount, Kevin O. Saunders, Drew Weissman, Barton F. Haynes, Stephanie A. Montgomery, Ralph S. Baric
93
17
Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization
2020 ·Journal of Virology ·Cody S. Nelson, Jennifer A. Jenks, Norbert Pardi, (unknown), (unknown), W. Daniel Edwards, Jason S. McLellan, Justin Pollara, Drew Weissman, Sallie R. Permar
44
18
Evaluation of a Single-Dose Nucleoside-Modified Messenger RNA Vaccine Encoding Hendra Virus-Soluble Glycoprotein Against Lethal Nipah virus Challenge in Syrian Hamsters
2019 ·The Journal of Infectious Diseases ·Michael K. Lo, Jessica R. Spengler, Stephen R. Welch, Jessica R. Harmon, JoAnn D. Coleman-McCray, Florine E. M. Scholte, Punya Shrivastava-Ranjan, Joel M. Montgomery, Stuart T. Nichol, Drew Weissman, Christina F. Spiropoulou
50
19
PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake breakdown →
2018 ·Journal of Controlled Release ·Hamideh Parhiz, Vladimir V. Shuvaev, Norbert Pardi, Makan Khoshnejad, Raisa Y. Kiseleva, (unknown), (unknown), Steven Tuyishime, Barbara L. Mui, Ying K. Tam, Thomas D. Madden, Michael J. Hope, Drew Weissman, Vladimir R. Muzykantov
154
20
Vaccine-delivered HIV envelope inhibits CD4+ T-cell activation, a mechanism for poor HIV vaccine responses
2006 ·Blood ·(unknown), Haitao Hu, Houping Ni, James A. Hoxie, Drew Weissman
15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshiharu Matsuura Breakdown of academic impact, for papers by David B. Weiner Breakdown of academic impact, for papers by Martin F. Bachmann Breakdown of academic impact, for papers by Bali Pulendran Breakdown of academic impact, for papers by Philip L. Felgner Breakdown of academic impact, for papers by David A. Jans Breakdown of academic impact, for papers by Dennis M. Klinman Breakdown of academic impact, for papers by James C. Paulson Breakdown of academic impact, for papers by Dimiter S. Dimitrov Breakdown of academic impact, for papers by Shane Crotty
Rankless by CCL
2026